Background: A previous study reported that amlodipine retarded coronary plaque progression in patients with coronary artery disease. The goal of this multicenter study was to determine which calcium-channel blockers (CCBs) other than amlodipine attenuated the progression of plaque volume (PV) accessed by intravascular ultrasound (IVUS).
any clinical trials have demonstrated that calciumchannel blockers (CCBs) reduce blood pressure (BP) as well as the incidence of cardiovascular events. The results of VALUE (The Valsartan Antihypertensive Long-term Use Evaluation) study, 1 CAMELOT (Comparison of Amlodipine vs Enalapril to Limit Occurrences of Thrombosis) study 2 and other studies have suggested that amlodipine, the most commonly used dihydropyridine CCB, can reduce the risk of coronary events. It was recently reported that this action was associated with the inhibitory effect of CCBs on plaque formation, as well as their antiatherosclerotic properties. 3 In the CAMELOT study of coronary artery dis-KOJIMA T et al.
ease (CAD) patients with normal BP, amlodipine had an equivalent antihypertensive effect similar to enalapril, but the incidence of coronary events was significantly lower in the amlodipine group. In patients with systolic BP (SBP) greater than the mean of all subjects' SBP especially, amlodipine treatment significantly slowed plaque volume (PV) progression compared to placebo. This observation could address 1 of the mechanisms of improvement of clinical outcomes in patients with CAD who are administered CCBs. However, these results were obtained from subanalysis of the trial, not the primary endpoint.
Furthermore, it remains uncertain whether CCBs other than amlodipine halt the progression of PV. A number of CCBs are available, and each one is assumed to have different antiatherosclerotic effects. It was reported that the dihydropyridine CCB, azelnidipine, inhibited atherosclerosis via its antiinflammatory and antioxidant effects. 4-6 Azelnidipine also inhibited neointima formation after stenting, which suggests that it has an antiatherosclerotic effect. 7, 8 We therefore planned the ALPS-J (Azelnidipine and Amlodipine Anti-Coronary Atherosclerosis Trial in Hypertensive Patients Undergoing Coronary Intervention by Serial Volumetric Intravascular Ultrasound Analysis in Juntendo University) study to investigate the inhibitory effect of the long-acting CCBs, azelnidipine and amlodipine, on plaque formation using 3-dimensional intravascular ultrasound (IVUS).
Methods

Study Design
ALPS-J was a prospective, randomized open-label blinded endpoint parallel group study. Patients who had hypertension and were scheduled for elective percutaneous coronary intervention (PCI) were enrolled as subjects. Azelnidipine (16 mg) or amlodipine (5 mg) was administered after PCI. Coronary PV in non-PCI sites of the culprit vessel was measured by IVUS immediately and at 48 weeks after PCI. The core-laboratory for quantitative assessments of IVUS data was blinded in terms of study group allocation. Prior to enrollment in the study, informed consent was obtained in writing from each subject. A documentation of the present study design was published before fixing the data 9 and was registered on ClinicalTrials.gov (Clinical Trials Government Identifier: NCT00294567) in accordance with the requirements established by the International Committee of Medical Journal Editors.
The study was conducted at 5 medical institutions. Inclusion criteria were patients aged 20-<79 years (at the time of giving consent) who were elective (not emergency) PCI with >75% stenosis and untouched non-culprit target lesion of <25% stenosis that could be imaged by IVUS. Patients with acute coronary syndrome (ACS), developed Q-wave myocardial infarction within 4 weeks of the start of the study, renal failure (Scr >2.0 mg/dl), failed PCI, moderate or severe congestive heart failure, and left main coronary artery occlusion ≥50% were excluded. Administration of 1 tablet of azelnidipine (16 mg) or amlodipine (5 mg) daily was started within 1 week after PCI and was administered orally once daily for 48 weeks. The drugs at the start of the study were fixed and continued during the study period except as mentioned below. The concomitant use of CCBs other than the 2 test drugs was prohibited during the study period. Concomitant use of antihypertensive drugs was allowed if the subjects were using such drugs before the start of the study. The dosing regimen was fixed during the study period. For HMG-CoA reductase inhibitors (statins) and other lipid-lowering drugs, the investigator decided on dose increases or use of additional agents as necessary, targeting a serum low-density lipoprotein cholesterol (LDL-C level <100 mg/dl in accordance with the Japan Atherosclerosis Society (JAS) Guidelines for Diagnosis and Treatment of Atherosclerotic Cardiovascular Disease 2007. 10 
Endpoints
The percent change in coronary PV at week 48 (48 W) compared with the baseline at the time of PCI was the primary endpoint using IVUS. A single lesion in a non-PCI site with a reproducible index side branch on the PCI vessel was investigated in each subject. The assessment site was selected at least 5 mm proximal to the PCI site. If the proximal site was impossible to be evaluated, the distal segment was used alternatively. Details of the IVUS procedure are published elsewhere. 11 In brief, the IVUS catheter Atlantis SR Pro2 (Boston Scientific, Natik, MA, USA) was used and advanced into the target vessel after 200 μg of intracoronary nitroglycerin, and a motorized pullback device withdrew the transducer at the speed of 0.5 mm/s. The consoles used were the Galaxy 2 system (Boston Scientific). Two independent experienced investigators performed the quantitative IVUS analysis at the central core-laboratory. All measurements were fulfilled at the end of the study. Baseline and follow-up IVUS images were reviewed side by side on a display and target sites were selected. The target segment for analysis was identified at a non-PCI site of the culprit vessel (>5 mm proximal or distal to the PCI site) based on some reproducible indices. Manual tracing was performed in every 0.3-mm cross-section and the software (echoPlaque2, INDEC systems Inc, Santa Clara, CA, USA) automatically interpolated the tracings of 15 cross-sections between 2 manually traced images. To eliminate any bias in the measurement of paired studies, the investigators doing the IVUS analysis were unaware of the patient group and did not know whether an examination was performed at baseline or follow-up. A lesion satisfying any of the following criteria was not be investigated: calcification, kinking, chronic complete occlusion, bypass graft site, site of coronary atherectomy before PCI, location at the left main trunk, small vessel (<2.0 mm), or location of distal protection device.
Definition of Events and Follow-up for Major Adverse Events
Follow-up visits were scheduled every 2 months. Major adverse events were defined as all-cause death, non-fatal myocardial infarction, hospitalization for congestive heart failure, target vessel revascularization, and stroke.
Sample Size and Data Analysis
The %change in PV due to treatment with CCBs as the primary endpoint has never been studied. In the CAMELOT study, however, the effects of antihypertensive drugs on PV were investigated by using the nominal %change in PV as a primary endpoint, a parameter that is similar to the percent change in PV in the present study. 2 The results of the CAMELOT study suggested that amlodipine inhibited the increase of PV. Based on this result, we assumed that neither azelnidipine nor amlodipine would increase PV. The noninferiority margin would be 6.5%, which was 75% of the %change in PV for the control group in the ESTABLISH study. 10 Based on the assumption that the standard deviation of the %change in PV would be 14% with an α level of 0.025 (1-sided) and a power of 80%, at least 74 subjects per group would be necessary. Considering that there would be some dropouts, we decided that the number of subjects per Azelnidipine and Amlodipine Anti-Atherosclerosis Trial group would be 100, with a total of 200 subjects.
An independent statistician with full access to the data conducted all statistical analyses. For the primary endpoint, the difference between the mean %changes in coronary PV on IVUS images in the 2 groups (μAz-μAm: mean percent change in coronary PV in the azelnidipine group [μAz] minus mean percent change in the amlodipine group [μAm]) and the 95% confidence interval (CI: 2-sided) of it was calculated based on an analysis of covariance (ANCOVA) model, treatment group and baseline value as covariates. If the upper limit of the 95%CI is less than 6.525%, azelnidipine is assumed to be non-inferior to amlodipine.
After the descriptive statistics, comparisons of continuous variables between the 2 groups were performed by the 2-sample t-test or Wilcoxon rank sum test, and those between the baseline and the follow-up by 1-sample t-tests or Wilcoxon signed rank test according to their distributions. Comparisons of categorical values between the 2 groups were performed by chi-square tests and Fisher's exact tests. We used general linear models to assess relationships between the percent change in PV and BP at 48 W, or to assess interobserver and intraobserver variabilities for measuring plaque area. The numbers of adverse events were assessed to determine safety profiles. The level of significance is P≤0.025 (1-sided) for the primary endpoint or P≤0.05 (2-sided) for other analyses. All statistical analyses were performed with the SAS system version 9.1 (SAS Institute, Cary, NC, USA).
Ethical Considerations and Role of the Funding Source
The study was conducted in accordance with the Declaration of Helsinki and the Ethical Principles in Clinical Studies published by the Japanese Ministry of Health, Labour, and Welfare. Prior to the study, the protocol and the informed consent form was reviewed from an ethical and safety perspective and approved by the institutional review boards of Juntendo University Hospital and each hospital. A grant for the study was provided by the Japan Heart Foundation.
Results
Baseline Characteristics and BP Changes
The disposition of patients in the present study is shown in Figure 1 . There were 199 patients: 100 randomized to azelnidipine and 99 to amlodipine. The mean patient age was 66.2± 8.7 years; 162 patients (81.4%) were men. There were 89 diabetics (44.7%) and 60 had metabolic syndrome (30.2%). Withdrawals from treatment numbered 84, with comparable numbers withdrawing from the azelnidipine (39 patients) and amlodipine (45 patients) groups. Among these patients, 46 were lost to follow-up after the first visit, and 13 withdrew consent. IVUS could not be performed in 15 patients and there was poor image quality of follow-up IVUS in 10 patients. Therefore, a total of 115 patients had evaluable IVUS images at both baseline and follow-up (61 in the azelnidipine group, 54 in the amlodipine group). The mean time between baseline and follow-up IVUS measurements was 48 weeks in all groups. Although the final analysis of IVUS parameter involved 115 patients, recalculation of the actual statistical power for the primary endpoint, 75%, indicated sufficient power remained.
The 2 groups had similar baseline characteristics, including age, sex, level of BP, risk factors for CAD, and use of β-blockers, angiotensin-converting enzyme inhibitors (ACEI), statins, and angiotensin type 1 antagonists ( Table 1) . Statins were used by 67.2% and 64.8% of patients at screening and approximately equal percentages of patients across the 2 groups received concurrent statin therapy during the study (80.3% for azelnidipine and 74.1% for amlodipine). BP significantly decreased from 138.5/74.1 mmHg at baseline to 129.1/69.7 mmHg at 48 W follow-up (P=0.003) in the azelnidipine group and Table 2) . BP at follow-up and the change in BP showed no significant difference between treatments. Table 3 shows the laboratory values at baseline and follow-up. The mean LDL-C level at baseline and follow-up was similar between the 2 groups. LDL-C decreased to 97.6 mg/dl during the study period in the azelnidipine group and to 95.1 mg/dl in the amlodipine groups. Azelnidipine induced significant reductions in high-sensitivity C-reactive protein (hs-CRP) and 8 isoprostane at follow-up compared with the levels at baseline and tended to an increase in adiponectin. In the amlodipine group, hs-CRP and 8-isoprostane levels were also reduced, but statistically not significant. Table 4 shows the profile and change in IVUS parameters. The percent change in coronary PV showed a significant regression compared with baseline for both groups (-4.67 (95%CI: -0.080 to -0.014) in the azelnidipine group, -4.85 (95%CI: -0.083 to -0.014) in the amlodipine group). Figure 2 shows a representive patient from each group at baseline and follow-up. Figure 3 illustrates the result of non-inferiority testing between azelnidipine and amlodipine regarding the primary endpoint. The difference in drug effects on the %change in PV (μp -μa) was evaluated and it had a mean value of 0.18% (95%CI: -4.62% to 4.98%). The upper limit of 95%CI of this difference was lower than the non-inferiority margin of 6.525%. Therefore, non-inferiority of azelnidipine to amlodipine was proved. During the azelnidipine treatment, vessel volume did not change whereas lumen volume was significantly increased. In contrast, vessel volume and lumen volume at follow-up decreased compared with baseline in the amlodipine group (Table 4 ). Figure 4 shows the relationships among various profiles in BP and %change in PV for the combined drug treatment groups. There was no statistically significant correlation between %change in PV and %change in BP at follow-up. Intra-and inter-variabilities for measuring plaque area in 
Laboratory Results
IVUS Results
Adverse Events
Azelnidipine and amlodipine was well tolerated during the study. There was a total of 18 adverse events, but only 1 death from cancer in the study period. There were no significant differences in the prevalence of adverse events between the azelnidipine and amlodipine group.
Discussion
The present study demonstrated improvement in coronary plaque after administration of two dihydropyridine CCBs, azelnidipine and amlodipine, in hypertensive patients undergoing elective PCI, independent of BP change. The current study proved that azelnidipine was non-inferior to amlodipine for a change in coronary PV. This result is congruous with that of the CAMELOT study 2 in which an IVUS substudy showed amlodipine retarded progression of atherosclerosis. In CAMELOT, the investigators compared amlodipine with ACEI in patients with CAD and normal BP and evaluated the atherosclerotic PV during 24 months. That trial was set up under optimal treatment of LDL-C (100 mg/dl) and high use of concomitant therapies. Under current evidence-based medicine IVUS revealed a trend toward less progression of PV in the amlodipine and enalapril group compared with placebo during the 24 months. There was less progression in the amlodipine than in the enalapril group. Our trial revealed that the degree of %change in PV was -5.2% for all patients, which compares strongly with the CAMELOT trial from the viewpoint of 5% plaque regression achieved during 48 weeks. CAMELOT and our ALPS trials had the same therapeutic strategy in common, but there are several differences between the 2 studies. There are several explanations for the greater reduction in PV compared with that achieved in CAMELOT. Only single plaque in the PCI target vessel was evaluated in the current trial whereas pancoronary PV was evaluated in CAMELOT. Changes in PV would be more exaggerated in a single plaque compared with pan-coronary plaque. Previous IVUS studies 12 suggested that Japanese patients showed more plaque regression than American patients undergoing the same intervention. 13 In statin trials, Japanese patients who received lower drug dose showed comparable regression of PV with less reduction in LDL-C.
The current findings were also compared with the results of PREVENT (The Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial) 14 study in which amlodipine therapy was significantly associated with slowing of the progression of carotid plaque, independent of BP change. Thus, it might be not surprising that CCB showed coronary plaque regression in the present trial.
The relationship between BP and regression of PV was not observed in this study as compared with a previous placebocontrolled trial 2 and there are several reasons for the lack of correlation. One might be that our study did not have a placebo arm not receiving CCB. Regression of plaque was observed in a broad spectrum of patients regardless of baseline and follow-up BP, which suggests that plaque regression is not related simply to the degree of BP reduction, but may depend on the use of CCB. Pleiotropic effects unrelated to BP reduction might be 1 of the mechanisms of plaque regression. In fact, CCB have proved to have pleiotropic effects included antiinflammatory, 4,15-17 enhancement of endothelial nitric oxide production, 8,18 inhibition of smooth muscle cell proliferation, 7,19 and antioxidant. 5,6,20 These actions would contribute to plaque regression in patients with CAD. In fact, our current trial demonstrated that CCB reduced by 40% CRP as an inflammation marker and increased adiponectin as a vascular protective agent by 33%. Furthermore, certain cellular changes in the developing plaque are characterized by a loss of normal calcium regulation. 6 This finding has led to interest in a potential antiatherosclerotic role for CCB, independent of their effects on vasodilatation.
The plaque regression in the current trial was substantially higher than might be expected for patients with the same observed LDL-C level as in the COSMOS (Multicenter Coro- nary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects) trial. 13 The COSMOS trial showed that rosvastatin exhibited significant plaque regression in Japanese patients with stable CAD; -38.6% reduction of LDL-C by rosvastatin was accompanied by a reduction in PV by -5.1%. In our study, LDL-C was reduced by only 6.2% because the target LDL-C was less than 100 mg/dl, based on the Japan Atherosclerosis Society Guideline. However, CCB achieved plaque regression by 5.0%, same as the plaque reduction in COSMOS, suggesting that hypertensive patients, even those who did not reach a low LDL-C level (LDL-C 80 mg/dl), showed comparable plaque regression, although LDL-C is a stronger promoter of plaque progression. One potential explanation is the high rates of use of other evidence-based medicine in our study. Our patients received background intensive treatment with antiplatelets and statins throughout the study to achieve LDL-C of 100 mg/dl and BP 130 mmHg. This total optimal medical therapy against such a background could contribute to an incremental benefit on plaque regression.
Study Limitations
The result was achieved in a small study sample. A substantial number of patients were excluded from IVUS analysis because of suboptimal image quality and severe calcification precluding accurate plaque size assessment. Therefore, some selection bias might exist. Any such change was likely to have affected both groups equally, however, and was therefore unlikely to have influenced the results. The observation of a single plaque in the culprit vessel may not represent the pancoronary nature of plaque. In this study, IVUS examination of all coronary arteries was not possible for ethical reasons. Another criticism may be that arteries undergoing PCI were included, which could have affected PV. However, the minimum lumen diameter of each evaluation site did not change throughout the trial (3.72±0.85 to 3.68±0.87 mm in the azelnidipine group, 3.77±0.76 to 3.69±0.71 mm in the amlodipine group) by quantitative IVUS analysis, which showed that the direct effect of the interventional procedures on vessel remodeling was slight. The dropout rate of patients in our trial was higher than in other IVUS studies, which we attribute to both the difficulty of maintaining patients on complex medical treatment for the course of the trial and IVUS quality issues. The absence of IVUS imaging at follow-up can potentially introduce biases into the analysis. The baseline characteristics of the completers and non-completers were similar and a post hoc analysis imputing efficacy value for non-completers did not alter interpretation of the trial.
Larger clinical studies are required, using IVUS as a primary end point, to conclusively determine the efficacy of CCB on regression of atherosclerosis. The net efficacy of CCB in plaque change was not proved conclusively because there was no placebo control group. However, we clarified that the CCBs were effective in stopping plaque progression in addition to standard medical treatment, especially in the achievement of the guideline LDL-C level and adjustment of BP using antihypertensive drugs other than CCBs.
Conclusion
ALPS-J demonstrated that that azelnidipine was non-inferior to amlodipine for primary efficacy. In addition to standard medical therapy including lipid-lowering therapy and BP control, the dihydropyridine CCBs resulted in retardation of PV progression in hypertensive patients.
